New injection aims to ease strain on failing hearts and lungs

NCT ID NCT05737940

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new injectable drug, AZD3427, could reduce high blood pressure in the lungs of people who also have heart failure. About 260 participants received either the drug or a placebo injection every two weeks for 24 weeks. The main goal was to see if the drug could make it easier for the heart to pump blood through the lungs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beverly Hills, California, 90211, United States
Research Site

La Jolla, California, 92093, United States
Research Site

New Haven, Connecticut, 06519, United States
Research Site

Baltimore, Maryland, 21287, United States
Research Site

St Louis, Missouri, 63136, United States
Research Site

Omaha, Nebraska, 68198, United States
Research Site

Rock Hill, South Carolina, 29732, United States
Research Site

Linz, 4020, Austria
Research Site

Vienna, 1100, Austria
Research Site

Edmonton, Alberta, T6G 2E1, Canada
Research Site

Vancouver, British Columbia, V6Z 1Y6, Canada
Research Site

Halifax, Nova Scotia, B3H 3A7, Canada
Research Site

London, Ontario, N6A 5A5, Canada
Research Site

Ottawa, Ontario, K1Y 4W7, Canada
Research Site

Toronto, Ontario, M5G 2N2, Canada
Research Site

Montreal, Quebec, H1T 1C8, Canada
Research Site

Beijing, 100034, China
Research Site

Changsha, 430033, China
Research Site

Guangzhou, 510100, China
Research Site

Kunming, 650051, China
Research Site

Prague, 10034, Czechia
Research Site

Prague, 12808, Czechia
Research Site

Prague, 140 21, Czechia
Research Site

Aarhus, 8200, Denmark
Research Site

Copenhagen, 2100, Denmark
Research Site

Berlin, 13353, Germany
Research Site

Cologne, 50937, Germany
Research Site

Frankfurt, 60596, Germany
Research Site

Jena, 07747, Germany
Research Site

Brescia, 25123, Italy
Research Site

Genoa, 16132, Italy
Research Site

Marche, 60126, Italy
Research Site

Milan, 20138, Italy
Research Site

Milan, 20142, Italy
Research Site

Trieste, 34149, Italy
Research Site

Bunkyō City, 113-8603, Japan
Research Site

Kasugai-shi, 487-0016, Japan
Research Site

Kure-shi, 737-8505, Japan
Research Site

Nagoya, 466-8560, Japan
Research Site

Sapporo, 060-8648, Japan
Research Site

Sunto-gun, 411-8611, Japan
Research Site

Toyama, 930-0194, Japan
Research Site

Deventer, 7416 SE, Netherlands
Research Site

Heerlen, 6419 PC, Netherlands
Research Site

Tilburg, 5022 GC, Netherlands
Research Site

Bialystok, 15-276, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Krakow, 31-202, Poland
Research Site

Warsaw, 02-005, Poland
Research Site

Warsaw, 04-628, Poland
Research Site

Wroclaw, 50-556, Poland
Research Site

Majadahonda, 28222, Spain
Research Site

Seville, 41009, Spain
Research Site

Toledo, 45007, Spain
Research Site

Valencia, 46026, Spain
Research Site

Gothenburg, 413 45, Sweden
Research Site

Huddinge, 141 57, Sweden
Research Site

Cambridge, CB2 0AY, United Kingdom
Research Site

Clydebank, G81 4DY, United Kingdom
Research Site

London, SW3 6NP, United Kingdom

Conditions

Explore the condition pages connected to this study.

HEART FAILURE PULMONARY HYPERTENSION (WORLD HEALTH ORGANIZATION GROUP 2)